Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CEA-HER2-CAR-T
- Development stage
- Unknown
- Lead developer
- PLA Army Specialty Medical Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CEA-HER2-CAR-T is a dual-targeted chimeric antigen receptor (CAR) T-cell therapy developed by the Third Hospital Affiliated To Army Medical University (Research Institute of Surgery) for the treatment of advanced gastric adenocarcinoma. This autologous cell therapy is engineered to simultaneously target Carcinoembryonic Antigen (CEA) and Human Epidermal Growth Factor Receptor 2 (HER2), two antigens frequently overexpressed in gastric cancer. By targeting two distinct tumor-associated antigens, the therapy aims to overcome tumor heterogeneity and reduce the risk of antigen escape, potentially improving therapeutic efficacy and durability compared to single-target CAR-T cells. It is currently being evaluated in Phase 1 clinical trials in China for patients with unresectable or metastatic gastric cancer who have failed prior therapies.
- Other names
- CEA/HER2-targeted CAR-T cellsdual CEA/HER2-targeted CAR-T
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on CEA-HER2-CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CEA-HER2-CAR-T.